Evidence map›Paper›PMID 29226809›Full record

Trial reportEBioMedicine2017

Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial.

Amir Krivoy, Roy Onn, Yael Vilner, Eldar Hochman, Shira Weizman, Amir Paz, Shmuel Hess, Roi Sagy, Shiri Kimhi-Nesher, Ehud Kalter and 6 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 6 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 6 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Vitamin D and Vitamin BDiseases (Basel, Switzerland) · 2026
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Analysis of clinical studies on clozapine from 2012-2022.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Amir KrivoyGeha Mental Health Center, Petah-Tikva, Israel; Sacker Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel; Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Petah-Tikva, Israel; Institute of Psychiatry, Psychology and Neuroscience, King's college London, London, UK. Electronic address: akrivoy@clalit.org.il.
Roy OnnGeha Mental Health Center, Petah-Tikva, Israel; Sacker Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Yael VilnerGeha Mental Health Center, Petah-Tikva, Israel.
Eldar HochmanGeha Mental Health Center, Petah-Tikva, Israel; Sacker Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel; Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Petah-Tikva, Israel.
Shira WeizmanGeha Mental Health Center, Petah-Tikva, Israel; Sacker Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.
Amir PazGeha Mental Health Center, Petah-Tikva, Israel; Sacker Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.
Shmuel HessGeha Mental Health Center, Petah-Tikva, Israel; Sacker Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.
Roi SagySacker Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel; Brill Mental Health Center, Tel-Aviv, Israel.
Shiri Kimhi-NesherGeha Mental Health Center, Petah-Tikva, Israel; Sacker Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.
Ehud KalterGeha Mental Health Center, Petah-Tikva, Israel; Sacker Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.
Tal FriedmanGeha Mental Health Center, Petah-Tikva, Israel; Sacker Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.
Zvi FriedmanGeha Mental Health Center, Petah-Tikva, Israel.
Gil BormantGeha Mental Health Center, Petah-Tikva, Israel.
Sharon TrommerSacker Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.
Avi ValevskiGeha Mental Health Center, Petah-Tikva, Israel; Sacker Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel.
Abraham WeizmanGeha Mental Health Center, Petah-Tikva, Israel; Sacker Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Israel; Laboratory of Biological Psychiatry, Felsenstein Medical Research Center, Petah-Tikva, Israel.
Tel Aviv University · ILGeha Mental Health Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile accumulating evidence suggests that vitamin D deficiency may be involved in the risk to develop schizophrenia and its outcome, there are no studies on vitamin D supplementation in this context. We sought to assess the effect of vitamin D supplementation on psychiatric, cognitive and metabolic parameters in chronic clozapine-treated schizophrenia patients.

methodsThis eight-week, randomized, double-blind, placebo-controlled clinical trial, recruited schizophrenia patients who had been maintained on clozapine treatment for at least 18weeks and had low levels of vitamin D (<75nmol/l) and total PANSS scores >70 (to ascertain the presence of residual symptoms). Patients were randomly allocated to either weekly oral drops of vitamin D (14,000IU) or placebo and subsequently assessed at two-week intervals for psychosis severity, mood, cognition and metabolic profile.

resultsTwenty four patients were randomly assigned to vitamin D (aged 39.4±9.6years, 75% males) and the other 23 patients to the placebo arm (aged 42.5±11.2years, 60.9% males). After eight weeks, the vitamin D group exhibited a significant increase in vitamin D levels (31.4 vs -0.4nmol/l, p<0.0001). There was no significant effect of vitamin D on psychotic, depressive or metabolic parameters. However, in the vitamin D group, there was a trend towards improved cognition (effect size=0.17, significance lost following Bonferroni correction).

conclusionsVitamin D supplementation was associated with a trend towards improved cognition, but did not affect psychosis, mood or metabolic status. It is possible that the robust decrease in the PANSS scores in both groups may have obscured an effect of vitamin D supplementation.

Indexed as

Dietary SupplementsAdultAntipsychotic AgentsClozapineCognitionDouble-Blind MethodFemaleHumansMaleMetabolic SyndromeMiddle AgedPsychotic DisordersSchizophreniaVitamin DAntipsychotic AgentsClozapineVitamin DClozapineCognitionMetabolic syndromeMoodSchizophreniaVitamin D

Identifiers

PMID29226809
PMCPMC5832639
OpenAlexW2773102718

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.